ACH-000143 is a potent and orally active melatonin receptor agonist, with EC 50 values of 0.06 nM and 0.32 nM for MT1 and MT2 , respectively
In Vivo
ACH-000143 reduces liver triglycerides and steatosis in diet-Induced obese rats . ACH-000143 is devoid of hERG binding, genotoxicity, and behavioral alterations at doses up to 100 mg/kg p.o., supporting further investigation of this compound as a drug candidate . ACH-000143 significantly reduces plasma glucose at 10 mg/kg (−16.4%, p < 0.05) and 30 mg/kg (−16.9%, p < 0.01) . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: High-fat diet rats . Dosage: 10 and 30 mg/kg. Administration: Orally, once daily for two months. Result: Significantly reduced the weekly BW gain on weeks.